gsk

What is Chronic Obstructive Pulmonary Disease (COPD)?

COPD is an umbrella term to describe conditions that limit airflow to the lungs, such as **chronic bronchitis** and **emphysema**¹



Patients with **COPD** experience narrowing of the airways, or airflow obstruction, which causes breathing difficulties.

The main cause of COPD is smoking¹

COPD develops slowly over years - most people are diagnosed aged 40 or older⁵





329 million

people have COPD² and it is the 3rd leading cause of death³ worldwide

It is also one of the 10 **most** disabling diseases globally²

COPD remains under-diagnosed.¹

COPD is diagnosed by assessment of symptoms and a spirometry test. This measures lung function, including how deeply a person can breathe and how fast air can move in and out of their lungs⁵



At its worst...

73% of COPD patients have **shortness of breath** at least **twice a week**⁴

Over half of people with COPD are woken up at night by coughing, wheezing or shortness of breath at least twice a week⁴

Symptoms of COPD include breathlessness, chronic cough and increased production of phlegm⁵



"It's as if my lungs can't expand properly, as if there is some form of external pressure bearing down on them." 13

29% of patients with COPD experience frequent exacerbations⁶

of patients who experience an exacerbation require hospitalisation⁶


An exacerbation is the sudden worsening in day-today symptoms, such as **increase in breathlessness, coughing and mucus production**^{5,7}

Every exacerbation can cause **permanent lung damage.**⁵ Repeated exacerbations can accelerate the **progression of the disease** ^{6,7}

3 out of 4 people with moderate COPD have a limited ability to carry out routine everyday tasks.8









The goals of COPD treatment are to **REDUCE the symptoms** and **REDUCE the risk of exacerbations** and **further disease progression**⁵

COPD needs better management



COPD contributes **50%** of European respiratory healthcare costs¹¹



The annual costs of healthcare and lost productivity due to COPD is €48.4 billion¹¹

Although major advances have been made in **COPD treatment** in recent years, **more needs to be done** to improve disease management and quality of life for people with COPD¹²



References 1. World Health Organization. Chronic obstructive pulmonary disease. Available from: http://www.who.int/respiratory/copd/en/ [Last accessed: Oct 2015] 2. Vos et al. Global Burden of Disease Study 2013. The Lancet. 2015; 386(9995); 743-800 3. World Health Organization. The top 10 causes of death. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/ [Last accessed: Oct 2015] 4. GSK Data on File - Continuing to Confront COPD International Study - Patient Survey Global Results 5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2015. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Sept2.pdf [Last accessed: Oct 2015] 6. Hurst et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. The

New England Journal of Medicine. 2010;3;1128-38 7. COPD Foundation. Staying Healthy and Avoiding Exacerbations. Available from: http://www.copdfoundation.org/What-is-COPD/Living-with-COPD/Staying-Healthy-and-Avoiding-Exacerbations.aspx [last accessed: Oct 2015] 8. Jones at al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respiratory Medicine. 2011:105(1):57–66 9. Vermeire. The burden of chronic obstructive pulmonary diseases. Respiratory Medicine. 2002:96;Suppl C:S3-101 10. Fletcher et al. COPD: The New Workplace Epidemic. 2011. Available from: https://www.copdfoundation.org/pdfs/COPD-Uncovered-Report-2011.pdf [Last accessed: July 2014] 11. European Lung White Book. The cost of respiratory disease. Available from: http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/the-cost-of-respiratory-disease/ [Last accessed: Oct 2015] 12. Punekar et al. COPD management costs according to the frequency of COPD exacerbations in UK primary care. International Journal of Chronic Obstructive Pulmonary Disease. 2014:9;65-73. 13. GSK Data on File – GSK Breathlessness in COPD Patient Survey. IPSOS Healthcare. April 2014.